Source: Eur Respir J 2009; 33: 219-221
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Cottin V., Fabien N., Khouatra C., Moreira A., Cordier J-F.. Anti-elastin autoantibodies are not present in combined pulmonary fibrosis and emphysema. Eur Respir J 2009; 33: 219-221

Member's Comments

No comment yet.

Related content which might interest you: The impact of emphysema in pulmonary fibrosis Source: Eur Respir Rev 2013; 22: 153-157 Year: 2013 Autoantibodies in patients with idiopathic pulmonary fibrosis Source: International Congress 2019 – Interstitial lung disease registries Year: 2019 Mortality in combined pulmonary fibrosis and emphysema patients is determined by the sum of pulmonary fibrosis and emphysema Source: ERJ Open Res, 7 (3) 00316-2021; 10.1183/23120541.00316-2021 Year: 2021 Subtypes of pulmonary emphysema on HRCT affect prognosis on combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Pulmonary hypertension in patients with idiopathic pulmonary fibrosis and combined pulmonary fibrosis and emphysema: hemodynamic severity Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle Year: 2018 Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis Source: Eur Respir J 2012; 39: 359-365 Year: 2012 Autoimmunity profile in patients with combined pulmonary fibrosis and emphysema (CPFE) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity Source: Eur Respir J 2005; 26: 586-593 Year: 2005 Clinical features of combined pulmonary fibrosis and emphysema Source: Annual Congress 2010 - Different patterns of interstitial lung disease Year: 2010 Serum levels of surfactant proteins in patients with combined pulmonary fibrosis and emphysema (CPFE) Source: International Congress 2015 – IPF pathogenesis Year: 2015 VEGF expression does not differentiate between idiopathic pulmonary fibrosis and pulmonary sarcoidosis Source: Eur Respir J 2007; 30: Suppl. 51, 574s Year: 2007 Diffuse pulmonary fibrosis and pulmonary emphysema associated with paradoxically normal spirometry Source: Eur Respir J 2006; 28: Suppl. 50, 100s Year: 2006 Systemic autoimmunity and  pulmonary fibrosis Source: International Congress 2017 – GR3 Scientific Grand Round: Autoimmunity in chronic lung disease Year: 2017 The clinical relevance of autoimmunity in idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease II Year: 2012 Procoagulant and antifibrynolitic activities strongly correlate with fibrosis and tissue turn-over markers in patients with active idiopathic pulmonary fibrosis and hypersensitivity pneumonitis Source: Annual Congress 2008 - Clinical aspects of interstitial lung disease Year: 2008 Clinical significance of combined pulmonary fibrosis and emphysema Source: International Congress 2017 – ILDs: clinical problems Year: 2017 Combined idiopathic pulmonary fibrosis and emphysema: functional characterization Source: Eur Respir J 2004; 24: Suppl. 48, 283s Year: 2004 Pulmonary arterial hypertension in combined pulmonary emphysema and fibrosis Source: Annual Congress 2005 - Pulmonary arterial hypertension diagnosis and therapy Year: 2005 Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013